Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 22

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 22
---
 Common Stock reserved for issuance upon the exercise of outstanding Warrants (as defined below), and 49,344 shares of Common Stock reserved for future issuances under the 2024 Plan. As of the Record Date, we had 1,429shares of Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”), 7shares of Series C convertible preferred stock, par value $0.0001 per share (the “Series C Preferred Stock”) issued and outstanding, 5,460shares of Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”) issued and outstanding and 3,816 shares of Series E convertible preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”) issued and outstanding. Based upon a conversion price of $0.05, the shares of Series A Preferred Stock are convertible into 28,580,000 shares of Common Stock, the shares of Series C Preferred Stock are convertible into 140,000shares of Common Stock, the shares of Series D Preferred Stock are convertible into 109,200,000shares of Common Stock and based upon a conversion price of $4.1625, the shares of Series E Preferred Stock are convertible into 916,757shares of Common Stock. If the Alternate Conversion Price is applied to determining the number of shares issuable upon conversion of the outstanding shares of Series A Preferred Stock, Series C Preferred Stock and/or Series D Preferred Stock the number of shares of Common Stock that would be issuable upon conversion thereof would be based upon 80% of the volume weighted -averageprice (“VWAP”) of the Common Stock during the five trading days immediately preceding the date of such conversion and, if Proposal No. 2 is approved, the number of shares of Common Stock that would be issuable upon conversion of the outstanding shares of Series E Preferred Stock would by based upon (i) 95% of such VWAP in the case of Alternate Optional Conversion (as defined in the Certificate of Designation of the Series E Preferred Stock (the “COD”)) or (ii) 90% of such VWAP in the case of Alternate Triggering Event Conversion (as defined in the COD). Procedure for Implementing the Reverse Stock Split The Effective Time, if approved by stockholders and implemented by the Company, will be the date and time set forth in the Certificate of Amendment that is filed with the Delaware Secretary of State. If